Article Text
Statistics from Altmetric.com
Footnotes
Disclosures Within the past 3 years, GWS served as a consultant for Osprey, Reva, Merck, CoreValve, Boston Scientific, Abbott Vascular, Evalve, AstraZeneca, Prescient, Eli Lilly-Daichii Sankyo partnership, Bristol-Meyers-Squibb-Sanofi partnership, Biosensors, Otsuka, The Medicines Company, Ortho-McNeil, Gilead, InspireMD, Atrium, Volcano, InfraReDx, Medtronic, Genentech, GlaxoSmithKleine, Miracor; received honoraria from Edwards and Vascular Solutions; and has equity in CoreValve, Savacor, Biostar I and II funds, MedFocus I, II and Accelerator funds, Calibre, FlowCardia, Ovalum, MediGuide, Guided Delivery Systems, Arstasis, Micardia, AccessClosure, Embrella and VNT.
Funding The HORIZONS-AMI trial.
Competing interests None.
Patient consent Obtained.
Ethics approval Numerous bodies in 17 countries.
Provenance and peer review Commissioned; internally peer reviewed.